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Despite the advent of sensitive and speciﬁc serologic testing, routine screening for celiac disease (CD) in diabetic populations
may not be universal practice, and many clinicians struggle to ﬁnd the optimal approach to managing CD in pediatric Type 1
diabetes (T1D) patients. While some clinicians advocate screening for CD in all patients with T1D, others are unsure whether this
is warranted. The diagnosis of patients who present with symptomatic CD, including malabsorption and obvious pathology upon
biopsy, remains straightforward, with improvements noted on a gluten-free diet. Many patients identiﬁed by screening, however,
tend to be asymptomatic. Evidence is inconclusive as to whether the beneﬁts of screening and potentially treating asymptomatic
individuals outweigh the harms of managing a population already burdened with a serious illness. This review focuses on current
knowledgeofCDinchildrenandyouthwithT1D,highlightingimportantelementsofthedisease’spathophysiology,epidemiology,
clinical presentation, and diagnostic challenges.
1. GeneticandClinicalConsiderations
Both Type 1 Diabetes (T1D) and celiac disease (CD) result
from a complex interplay between genetic susceptibility and
environmental exposure. CD is an autoimmune enteropathy
characterized by immune-mediated damage to the small
intestinal mucosa triggered by ingestion of gluten, a protein
complex found in wheat, rye, and barley [1, 2]. CD and
T 1 Dh a v ec o m m o na u t o i m m u n eo ri gi n s .B o t ha r ea s s o c i a t e d
with the major histocompatibility complex class II antigen
DQ2 encoded by the alleles, DQA1∗501 and DQB1∗201,
thusprovidingacommongeneticbasisfordiseaseexpression
[3, 4]. Recent work has also revealed 7 shared non-HLA
loci associated with CD and T1D including RGS1 on chro-
mosome 1q31, IL18RAP on chromosome 2q12, TAGAP on
chromosome 6q25, PTPN2 on chromosome 18p11, CTLA4
on chromosome 2q33, SH2B3 on chromosome 12q24, and a
32-bp insertion-deletion variant on chromosome 3p21 [3].
This shared genetic basis is strongly suggestive of a common
etiology for both conditions. An increasing body of evidence
d e ri v e df r o ma n i m a lm o d e l so fT 1 Da sw e lla sh u m a ns t u d i e s
[5] suggests that T1D and CD share many causative genetic
and environmental factors and highlights the emerging role
of dietary antigens in T1D development. This “intestine-
diabetes” link supposes that consumption of gluten, alone or
acting synergistically with local microbial factors, results in
altered gut permeability and mucosal immunity which may
predisposethedevelopmentofT1D[6].Furtherinsightsinto
our understanding of T1D and other autoimmune condi-
tions will likely be forthcoming through this line of research
examining the impact of environmental triggers, altered
immune reactivity, and abnormal intestinal permeability.
2. Epidemiology
Mostestimates puttheprevalenceofCD atcloseto1% ofthe
general population [7–10], and recent evidence suggests that
serologic prevalence rates have increased fourfold in the past2 International Journal of Pediatric Endocrinology
Table 1: Prevalence of Biopsy-Proven CD in T1D in Pediatric Populations Around the World.
Geographic Location Author N Age (years) Prevalence CD + DM (%) Study Design
Europe
Finland 1996 [14] Saukkonen et al. 776 2–21 2.4 Cohort
Spain 1998 [15] Roldan et al. 177 15.4 ±5.43 . 9 C o h o r t
Austria 2003 [16] Crone et al. 157 14.8 5.1 Prospective Cohort
Denmark 2006 [17] Hansen et al. 106 10.8 (median) 10.4 Cross-sectional
United Kingdom 2007 [18] Goh and Banerjee 113 12.1 4.42 Cross-sectional
Sweden 2008 [19] Larsson et al. 300 9.2 9.67 Prospective cohort
Italy 2008 [20] Salardi et al. 331 8.1 ±4.3 6.65 Retro/Prospective
Greece 2009 [21] Karavanaki et al. 144 12.3 ±4.6 3.47 Cross-sectional
North America
United States 2001 [22] Aktay et al. 218 4–21 4.6 Cross-sectional
Canada 2001 [23] Gillett et al. 233 children 7.7 Cross-sectional
South America
Brazil 2005 [24] Baptista et al. 104 10.5 ±4.3 4.8 Cross-sectional
Africa
Algeria 1996 [25] Boudraa et al. 116 1–19.5 16.4 Cohort
Libya 2003 [26] Ashabani et al. 234 12.8 ±5.4 10.3 Cross-sectional
Egypt 2005 [27] Salah et al. 200 11.2 4.0 Cross-sectional
Tunisia 2007 [28] Mankai et al. 205 11 (median) 5.3 Prospective cohort
Australia
Australia 2000 [29] Smith et al. 218 9.9 ±3.8 5.7 Cross-sectional
Middle East
Saudi Arabia 2003 [30] Al-Ashwal et al. 123 young patients 4.9 Cross-sectional
Iran 2009 [31] Fallahi et al. 96 12 (median) 6.2 Cross-sectional
50 years [11]. CD is also a global health condition that aﬀects
both developing and developed nations (Table 1). Clinicians
shouldremainvigilantasCDisincreasinglyobservedinnon-
Caucasian groups, particularly in those of North African and
North Indian (Punjabi) ancestry, where incidence rates have
been reported as 8 times greater than the general population
[12, 13].
T h ep r e v a l e n c eo fC Di nT 1 Dh a sb e e nr e p o r t e dt ob e5 –
7 times greater than the general population [22, 23, 32–34]
with increased prevalence rates among most ethnic groups
[14–31, 35]. Although sampling methods and diagnostic
criteria diﬀer among studies, rates of biopsy-proven CD in
pediatric T1D range from as low as 2.4% in Finland [14]t o
16.4% in Algeria [25]( Table 1).
3. CD Presentation
The classic presentation of CD describes symptoms related
to gastrointestinal malabsorption and includes malnutrition,
failure to thrive, diarrhea, anorexia, constipation, vomiting,
abdominal distension, and pain. This predominance of
gastrointestinal symptoms is most common in children
younger than three years of age [36]. Nongastrointestinal
or atypical symptoms of CD include short stature, pubertal
delay, fatigue, vitamin deﬁciencies, and iron deﬁciency
anemia and are more commonly observed in older children
[37].
The classical presentation of CD can occur in T1D
patients, but many patients with CD and T1D are either
asymptomatic (silent CD) or present with only mild symp-
toms [34, 38]. In a recent study from a North Ameri-
can CD clinic, 71.4% of children with diabetes reported
no gastrointestinal symptoms at the time of a positive
screen [36]. In reality, however, the presence and timing
of “symptoms” in screened T1D patients is likely more
complex. A UK study evaluated children with CD and
T1D and included all retrospective data on symptoms from
multiple time points obtained from notes and symptom
questionnaires administered at diabetes and celiac clinics.
The study reported that 13/17 (76.4%) of patients had at
least 1 gastrointestinal symptom. A questionnaire evaluating
a longitudinal assessment of symptoms showed that T1D
patients reported more gastrointestinal symptoms over the
course of the diagnostic work-up. Initially, 86% of patients
described no symptoms, but this proportion dropped to
22% at the time of intestinal biopsy [39]. While this may
represent bias as to the impact of screening and counseling,
it emphasizes the complex clinical spectrum of CD. For
example, children may be less likely to show overt growth
failure but can have weight and height measures at a lower
growth percentile and complain of nonspeciﬁc symptoms,
including anorexia and lassitude [40]. Some patients are
overweight or obese at diagnosis; 11.2% of children with CD
had a BMI greater than the 90th percentile in a recent USInternational Journal of Pediatric Endocrinology 3
study [34]. In many high-risk populations, including T1D,
CD can present with multiple subtle, clinical features for
which clinicians must be vigilant.
4. ScreeningandDiagnosis
Theintroductionofserologictestinghasfacilitatedscreening
at-risk populations for CD, including conditions such as
T 1 Da sw e l la sD o w na n dT u r n e rs y n d r o m e s[ 7, 41]. Before
its use, the only tool available for CD diagnosis was small
bowel biopsy [42]. Serologic testing has also led to a rise
in the rates of diagnosis of CD [43, 44] and altered the
clinical pattern of CD presentation. Recent Canadian data
show a threefold increase in incidence rates (2 per 100,000
in 1996 to 7.3 cases per 100,000 in 2006) on the basis of
serologic testing. Interestingly, rates of classical CD observed
in younger children remained stable from 1990 to 2006,
leading to an increase in the mean age at diagnosis, with the
majority of newly diagnosed CD children identiﬁed as part
of high-risk groups, including T1D [37].
Among the antibodies found in CD, screening tests
for endomysial (EMA) IgA and tissue transglutaminase
(TTG) IgA have been reported to be the most sensitive and
speciﬁc. Antigliadin antibodies have also been used in CD
screeningbutarenolongerrecommendedbecauseofinferior
sensitivities and speciﬁcities relative to EMA and TTG. A
review of 32 studies using EMA IgA found a speciﬁcity
of 90% to 100% (mean 99%) and sensitivity of 86% to
100% (mean 95%). The speciﬁcity of TTG IgA among 27
studies ranged between 86% and 100% (mean 95%), and the
sensitivity ranged between 61% and 100% (mean 87%). As
these studies were done in a research setting, it is important
to note that the accuracy reported may be greater than that
foundin clinical practice.Although EMA appears to be more
sensitive and speciﬁc than TTG, this is because some studies
used guinea pig TTG which is less sensitive and speciﬁc than
human recombinant protein TTG. A comparison of studies
using human recombinant TTG IgA and EMA IgA found no
signiﬁcant diﬀerence [45]. The American Gastroenterology
Association’s medical position statement on the diagnosis
and management of celiac disease recommends use of the
TTG IgA test for the initial detection of CD as it is less
time consuming and operator dependent than the EMA
IgA test [46]. It must be emphasized that all diagnostic
tests must be performed while the patient is on a gluten-
containing diet. Furthermore, serologic testing for children
less than 5 years of age is less reliable due to age related
changes in immunogenicity. It is also unfortunate that the
cost of TTG testing outside of hospital is not covered in
many jurisdictions, thereby reducing the availability of CD
screening in community-based practices.
IgA deﬁciency occurs more commonly in CD than in
the general population, making the identiﬁcation of certain
patients with CD using serology diﬃcult [47]. While studies
looking at IgA deﬁciency in the general population have
reported rates from 1 in 400 to 18,500 people [48–50], in the
C Dp o p u l a t i o nr a t e sh a v eb e e nr e p o r t e da sh i g ha s1i n3 9t o
57 people [51, 52]. If a partial or absolute IgA deﬁciency is
found, EMA IgG or TTG IgG tests are recommended as both
are sensitive and speciﬁc [46].
Once patients are identiﬁed as screen positive, they
should be referred to a gastrointestinal specialist for evalua-
tion and consideration of intestinal biopsy. Biopsy remains
the gold standard of diagnosis, and endoscopic evaluation
with biopsies from multiple intestinal sites is preferred
because CD can present with variable biopsy ﬁndings, and
nonfocal or “patchy” histopathologic lesions have been
observedfromduodenalsamplesinover50%ofchildrenand
up to 25% of adults [53, 54].
5. CurrentScreeningRecommendations
Consensus-based guidelines developed by the Canadian Dia-
betes Association (CDA), the American Diabetes Association
(ADA), the International Society for Pediatric and Ado-
lescent Diabetes (ISPAD), the North American Society for
Pediatric Gastroenterology and Hepatology (NASPGHAN),
and the National Institutes of Health (NIH) diﬀer in their
screening and treatment recommendations for patients with
T1D (Table 2)[ 55–59]. The ADA recommends screening
T1D patients for CD and placing all children with a
conﬁrmed diagnosis of CD on a gluten-free diet (GFD)
[58]. ISPAD suggests that while it seems sensible to put an
asymptomatic child on a GFD to avoid the development
of complications, limited data are available to support this.
Therefore, they recommend that children with conﬁrmed
CD and T1D receive support from a pediatric dietician [55].
NASPGHAN recommends screening T1D patients for CD
and a GFD for asymptomatic children with an associated
condition such as T1D but acknowledges that there is little
evidencetosuggestthataGFDleadstoimprovementsindia-
betes in the short-term. Conversely, current CDA guidelines
advise screening symptomatic T1D patients and emphasizes
informing parents that the treatment of asymptomatic CD
in T1D is controversial [57]. An NIH sponsored consensus
document (2004) also recommends screening symptomatic
T1D patients for CD only and treating all patients with
biopsy-proven CD [59]. These disparate recommendations
leave clinicians without a concrete method of patient man-
agement and speak to the absence of available literature for
development of an evidence-based approach.
6. Treatment witha Gluten-FreeDiet
Currently, the only eﬀective treatment in use for CD is
a GFD, although new treatments are being developed. As
deﬁned, a GFD excludes wheat, rye, and barley and should
b es t r i c t ,a se v e nt r a c ea m o u n t so fg l u t e nm a yp r o v o k e
intestinal inﬂammation [59]. However, there is no accepted
deﬁnition of what constitutes a “safe” amount of dietary
gluten. Uncontaminated dry-rolled oats in limited amounts
are considered safe for inclusion as part of a GFD, but care
must be exercised as there is a potential for contamination
with gluten during processing [60].
For symptomatic patients, adherence to a GFD most
often leads to resolution or improvement of symptoms4 International Journal of Pediatric Endocrinology
Table 2: Clinical Recommendations for Screening and Treatment of CD in T1D.
Organization Indications for
Screening/Investigation Screening Test Frequency
Treatment
Symptomatic Asymptomatic
International
Society for
Pediatric and
Adolescent
Diabetes [55]
(Consensus Based)
(i) Diarrhea, ﬂatulence
(ii) Unexplained poor
growth
(iii) Abdominal pain
(iv) Dyspeptic symptoms
(v) Anemia
(vi) Recurrent aphthous
ulceration
(i) IgA levels
(ii) EMA and TTG
IgA
( i )A tt i m eo fT 1 D
diagnosis and every
second year thereafter
(ii) If clinical situation
suggests possible CD, or if
the child has ﬁrst-degree
relative with CD, more
frequent assessment is
indicated
Gluten-free diet
Gluten-free diet
may be considered
justiﬁed with goal
of reducing risk of
complications.
Canadian Diabetes
Association [57]
(Evidence Grade
D: Consensus)
(i) Symptoms of classic or
atypical CD
(ii) Poor linear growth
(iii) Fatigue
(iv) Recurrent GI
symptoms
(v) Poor weight gain
(vi) Anemia,
(vii) Unexplained frequent
hypoglycemia/poor
metabolic control
(i) TTG
(ii) IgA levels (i) Based on clinical
symptoms Gluten-free diet
Parents should be
told treatment of
asymptomatic CD
with gluten-free
diet in T1D is
controversial.
American Diabetes
Association [58]
(Evidence Grade E:
Consensus)
(i) Failure to gain weight
(ii) Gastroenterologic
symptoms
(iii) Growth failure
(iv) Weight loss
(v) Recent T1D diagnosis
(i) TTG or EMA
(ii) IgA levels
(i) Periodic re-screening
of asymptomatic
individuals or if
indications for screening
develop
Gluten-free diet
All children with
conﬁrmed
diagnosis of CD
should be put on a
gluten-free diet.
North American
Society for
Pediatric
Gastroenterology,
Hepatology and
Nutrition [56]
(Consensus Based)
(i) Non-GI symptoms of
CD (osteoporosis, short
stature, dermatitis
herpetiformis, delayed
puberty, iron-deﬁcient
anemia)
(ii) Other (autoimmune
thyroiditis, T1D, Williams
syndrome, Down
syndrome, Turner
syndrome)
(i) TTG IgA
(i) Asymptomatic
individuals who belong to
high risk groups with
negative serological tests
should be considered for
repeat testing at intervals
Gluten-free diet
Gluten-free diet
recommended for
asymptomatic
children with an
associated
condition such as
T1D.
[17, 61]. Conversely, nonadherence to a GFD in patients
with symptomatic CD is the primary reason for a lack of
improvementfollowingCDdiagnosis[62–64].Asinglelong-
term follow-up study from France retrospectively examined
61symptomaticpatientsdiagnosedinchildhoodwithbiopsy
positive CD who subsequently discontinued the GFD [65].
After a latency period of 10 years on a normal, gluten
containing diet, 47% reported mild clinical symptoms, and
80% had evidence of CD on repeat intestinal biopsy.
It remains unclear whether asymptomatic patients expe-
rience long- and/or short-term health related beneﬁts from
following a GFD [38, 66]. To our knowledge, no clinical
studies have followed the natural progression of CD in
patients with asymptomatic CD, and any beneﬁcial eﬀects of
strict compliance with a GFD in asymptomatic patients with
CD and T1D remain unknown.
7. Adherence to a GFD
Adherence to a GFD varies among patients with CD, with
rates ranging from 23.8 to 81% (Table 3)[ 38, 61, 67–75].
In children with CD and T1D, less than 30% were strictly
compliant with a GFD [17, 67, 71]. The majority of patients
were, at minimum, ingesting trace amounts of gluten. This
variability in compliance stems from diﬀerences in criteria
used to deﬁne compliance, the methods used to measure
compliance, whether subjects were identiﬁed by symptoms
or screening, and age at diagnosis. Lower compliance has
been found in adolescents diagnosed via mass serological
screening than in patients matched for age who were
diagnosed with typical symptoms during childhood [61, 76].
Patients diagnosed with CD at a very young age have been
found to have the highest rates of compliance. In Sweden,International Journal of Pediatric Endocrinology 5
Table 3: Levels of GFD Compliance in Pediatric Populations.
Author Country n Age Length of
Follow-up Mode of Follow-up GFD Compliance (%)
Westman et al. 1999 [67] Australia 20 CD + DM 6.9–17.4 N/A 7 day food record 30 (strict)
30 (trace gluten diet)
40 (non-compliant)
Mariani et al. 1998 [68] Italy 47 CD 15.2 ±2.3 N/A Diary 53.2 (compliant)
EMA∗ 46.8 (non-compliant)
Greco et al. 1997 [69] Italy 306 CD 12 Unclear Diary 73 (strict)
GI consultant 15 (occasional gluten)
Repeat Biopsy
12 (frequent
transgressions/full
gluten-containing diet)
van Koppen et al. 2009 [70] Netherlands 32 CD 12–14 10 years Interview 81 (compliant)
19 (non-compliant)
Saadah et al. 2004 [71] Australia 21 CD + DM 7.5 1 year Structured telephone
questionnaire 25.0 (Excellent)
60.0 (Good)
5.0 (Fair)
10 (Poor)
Wagner et al. 2008 [72] Austria 283 CD 10–20 N/A Questionnaire 80.8 (strict)
14.9 (2-3
transgressions/month)
4.3 (more frequent
transgressions)
Hopman et al. 2006 [73] Netherlands 132 CD 16.6 ± 4.4 N/A Questionnaire 75 (strict)
23 (occasional
consumption)
2 (non-compliant)
Jadresin et al. 2008 [74] Croatia 71 CD 12 Questionnaire 53 (strict)
26.4 (small amounts of
gluten)
20.6 (non-compliant)
Fabiani et al. 1996 [61] Italy 28 CD 11–14 23 ±7 months Questionnaire 52.2 (strict)
EMA 47.8 (occasional
transgression)
Rami et al. 2005 [38] Austria 74 CD + DM 6.5 ±4.13 .3 ±1.9 years EMA 44.6 (compliant)
55.4 (non-compliant)
Anson et al. 1990 [75] Israel 43 CD <18 6.9 ±3.3 Assessment of
symptoms, biopsy and
antireticulin antibodies
70 (compliant)
28 (non-compliant)
2 (unclassiﬁed)
∗EMA refers to antiendomysial antibody.
only 36% of adults diagnosed with CD over the age of 4 years
were compliant, as compared to 80% diagnosed before the
age of 4 [77].
It is challenging for clinicians and dieticians to assess
individual patient adherence to the GFD, especially in
older children and adolescents who eat outside of parental
supervision. Dietary interviews may be helpful but are often
nonstandardized, time intensive, and subjective. Further-
more, few physicians and dieticians are suﬃciently well
trained to evaluate GFD adherence. Repeat CD serologic
testing (TTG IgA), with declines noted after 6 months on
a GFD, may be used to follow adherence, but these tests
have been shown to have variable sensitivity in evaluating
gluten exposure in adult studies [78]. Reassessment with
repeatendoscopyisalsoavailabletodirectlyassesspathology,
albeitaninvasive,expensiveandlessviableoptionforroutine
pediatric cases. Despite the diﬃculty of assessing individual
GFD adherence, some key questions posed to CD patients
including the frequency of purposeful gluten ingestion and
an individual patient or family’s ability to follow a GFD6 International Journal of Pediatric Endocrinology
Table 4: Metabolic Control Measures Following a GFD in CD Positive Patients.
Author Study Design N Age Growth Improvement
Eﬀect
HbA1C
Change
Hypoglycemic
Episodes DM CD + DM
Hansen et al. 2006
[17]
Cohort (2 year
follow-up) 236 33 1.5–16 Ht NS∗ NS ↓↓
Wt ↑↑
Sanchez-Albisua et
al. 2005 [81]
Longitudinal (1–5
years follow-up) 263 9 12 ±5 years Ht ↑↑∗∗ NS ↓↓
Wt NS
Saadah et al. 2004
[71]
Cohort (1 year
follow-up) 42 21 1.6–12.9 Ht NS NS NE
Wt ↑↑
BMI ↑↑
Rami et al.2005
[38]
Case-control (3.3 ±1.9
years follow-up) 195 98 10.0 ±5.4H t N S N S N S
BMI NS
Sun et al. 2009 [82] Case-Control (2 year
follow-up) 49 49 6.0 ±4.1H t N S ↑↑ N/A
Wt NS
BMI NS
∗Subgroup analysis excluding patients >14 at study onset found signiﬁcant increase in Ht SDS.
∗∗Data for well-complying patients.
NE: not evaluated.
NS: not signiﬁcant.
outside the home are strongly predictive of GFD adherence
[79, 80].
The beneﬁts of adherence with a GFD in patients with
T1D in regards to clinically relevant outcomes are mixed
[17, 38, 71, 81, 82]( Table 4). Height (SD) was reported
to increase in those well-compliant with a GFD in one
study [81], while other studies reported no signiﬁcant
improvements [17, 38, 71, 82]. Improvements in weight
[17, 71]a n dB M I[ 71] have also been reported, but this
is not true for all studies [38, 81, 82]. A single pediatric
study has reported a signiﬁcant increase in HbA1C levels
after following a GFD [82], while the remainder have
reported no change [17, 38, 71, 81]. A decrease in the
number of hypoglycemic episodes was noted in some studies
[17, 81] but not in another [38]. The discordant ﬁndings
among studies, small numbers of patients studied, as well as
lack of distinction between symptomatic and asymptomatic
patients, make it diﬃcult to comment on the real impact of
adherence to a GFD in patients with T1D.
8.BarrierstoAdherence
While a GFD is the current method of treatment for CD,
few studies have examined the practicality of following it,
particularly among adolescents and children with T1D. One
area with limited data is the barriers to compliance with a
GFD among adolescents and children. Factors reported to
aﬀect the likelihood of compliance include unavailability of
gluten-free food, problems with sensory acceptance, inade-
quate support from family and peers, absence of symptoms
following ingestion of gluten, and lack of knowledge of the
health-related harms of gluten ingestion [83].
An additional barrier to adherence is the economic
feasibility of living with the GFD [84, 85]. Gluten-free food
is considerably more expensive than its gluten-containing
counterpart. A cost comparison found that the unit price
of gluten-containing food was $0.61 ± 0.38 as compared
with $1.71 ± 0.93 for gluten-free food. Gluten-free foods
were on average 242% ± 212 more expensive than gluten-
containing foods [85]. This increase in cost is largely related
to the fact that additional starches and additives are added
to gluten-free items to mimic the properties of wheat-based
ﬂours [86].
The availability of gluten-free food measured in 5
diﬀerent US states was also found to be signiﬁcantly less
than food containing gluten [84] and has been reported as
a barrier to compliance [83]. The availability of gluten-free
food has not been examined in developing countries. As the
number of people diagnosed with CD continues to grow,
ensuring the ready availability of gluten-free food worldwide
and integrating it into the general food supply will become
increasingly important. In Canada, in 2008 Health Canada
proposed changes to food labeling regulations; speciﬁcally,
the label “gluten free” would mean that a product does not
contain wheat, oats, barley, rye, or any ingredients derived
from these grains [87]. While useful, this would not address
cross contamination of bin foods such as rice, where the
consumer would not expect to ﬁnd gluten.International Journal of Pediatric Endocrinology 7
9.WellbeingandQualityofLife
Another important consideration is the putative eﬀect of a
GFD on wellbeing in children with T1D [88]. T1D alone has
been shown to have a signiﬁcant negative impact on quality
of life in adolescents [89–91]. In adult diabetes patients,
psychosocial issues have been found to supersede metabolic
measures in predicting negative outcomes [92]. Living with
a GFD may impact quality of life. Symptomatic adults with
CD have been found to have poorer quality of life than
asymptomatic patients at diagnosis; this improves only in
symptomatic patients with either strict or partial adherence
with a GFD after 1 year [92, 93]. Another study found no
change in quality of life in screen-detected patients following
a GFD [94]. A recent study in adolescents with CD aged
10–20 years observed worse quality of life in those not
compliant with the GFD, with older teens experiencing more
school and social problems than healthy teen controls [72].
Overall, these data emphasize the importance of evaluating
psychological well-being in pediatric CD, particularly the
asymptomatic at-risk group. This is especially relevant in the
context of T1D, where patients with diabetes must manage
two chronic conditions.
10.EmergingAlternativestothe GFD
Alternatives to the GFD are being developed, and these
novel treatments may lead to viable treatment opportunities.
Enzyme therapy products using combinations of endo-
protease/endopepitidases may increase amount of ingested
gluten that can be safely tolerated [95]. Intestinal perme-
ability inhibitors may reduce small intestine permeability
upon gluten exposure, thus decreasing inﬂammation [96].
Modalities to target the HLA molecule using DQ2-peptide-
blockers may prevent DQ2 mediated antigen presentation to
T cells, an important event in the pathogenesis of CD [97].
These modalities are currently investigational but may allow
for alternative adjunct or replacement treatment strategies
for the GFD in CD-aﬀected patients in the future.
11.CD-RelatedComplications: AreThey
SimilarinT1D-ScreenedPatients?
A leading reason for screening asymptomatic individu-
als is to institute early treatment, thereby mitigating the
risk of long-term CD-related complications, speciﬁcally
osteopenia/osteoporosis, small bowel lymphoma, reproduc-
tive problems, and the overall enhanced mortality associated
with CD [98].
11.1. Bone Health. In children, osteoporosis is deﬁned as
a general skeletal disorder characterized by low bone mass
and a microarchitectural deterioration of bone tissue which
resultsinincreasedbonefragilityandincreasedsusceptibility
to fractures [99]. Osteoporosis represents the most insidious
complication with greatest potential public health impact of
early identiﬁcation of CD in T1D patients. It is important to
appreciate that during childhood bone mass development,
bone mineral content increases in a linear fashion and is
related to weight, height, and pubertal development. Other
signiﬁcant determinants of peak bone mass include adequate
nutritionwithrespecttocalciumandvitaminDstatus.These
work in concert with sex steroids and growth hormone to
contribute to the signiﬁcant changes that occur during the
pubertal time period with the eventual attainment of peak
bone mass in the second decade of life [100].
CD has been associated with decreased bone mineral
density (BMD) in adolescents and children [101–105]. Tau
et al. [104] reported mean lumbar spine BMD Z-scores as
measuredbyDXAat −1.36±1.20in24childrenatdiagnosis;
this improved by over 1 SD after 1 year on the GFD.
A Canadian study found no diﬀerences in BMD Z-scores
between children with CD (9.6 ± 3.7 years) who presented
with or without symptoms at diagnosis. However BMD Z-
scores were low in both groups with 16.7% of symptomatic
children and 14.3% of asymptomatic children with a Z-score
less than or equal to −2S D[ 106]. A single long-term follow-
up study from France retrospectively examined symptomatic
patients diagnosed in childhood with biopsy positive CD
whosubsequentlydiscontinuedtheGFD[65]. After a latency
period of 10 years on a normal diet, 70% had low BMD Z-
scores between −1a n d−2.5SD .
The etiology behind the low BMD seen in adolescents
and children with CD remains unclear. Decreased calcium
intake and absorption has been reported [107]. However,
somestudieshavereportedserumcalciumlevelstobewithin
the normal range at CD diagnosis [104, 108], with a small
increase following a GFD [108]. Vitamin D levels (25 OH
D) in CD patients have been shown to be comparable
to controls at diagnosis, although levels increased on the
GFD [104, 109]. Studies looking at parathyroid hormone
have shown mixed results, with several reporting normal
values [103, 104, 108] and others reporting elevated levels
of parathyroid hormone in CD patients at diagnosis [110–
112]. An imbalance between the cytokines osteoprotegerin
and receptor activator of nuclear factor KappaB ligand
(RANKL) is an alternate explanation for low BMD in CD.
The regulatory role of cytokines on cells involved in bone
formation and breakdown has been well documented [113–
116]. RANKL is expressed by osteoblasts and activates the
development of osteoclasts. When the macrophage stimu-
lating factor is present, RANKL activates its receptor RANK
[117], leading to formation and activation of osteoclasts
[118]. Osteoprotegerin inhibits RANKL activity by binding
to it [119]. Evidence of an imbalance in the levels of RANKL
and osteoprotegerin has been found in adult patients with
CD [120, 121], suggesting that they may play a role in
decreased BMD in CD.
Low BMD has also been found in persons with T1D,
[122–124] and may further increase the risk of osteoporosis
inadulthood[125,126].Studieshavereportedthatfollowing
a GFD improves BMD in CD [101–103, 127–129]. But
few studies have examined BMD levels in adolescents and
children with CD and T1D [130–132]. Results have been
discordant with some studies reporting lower BMD in
patients with CD and T1D [130, 132] and another ﬁnding
no diﬀerence [131].8 International Journal of Pediatric Endocrinology
11.2. Lymphoma. The increased incidence of non-Hodgkin
lymphoma in CD has been well established [133, 134].
Enteropathy-associated T-cell lymphoma (EATCL) specif-
ically has been estimated to occur 50 times more in
symptomatic CD than in the general population [135].
Following a strict GFD for a minimum of 5 consecutive
years has been shown to protect against the development of
lymphoma [135]. To our knowledge, only one retrospective
study in Switzerland has reported on the incidence of EATCL
in patients with CD and T1D. Investigators identiﬁed 10
cases of EATCL in the Swiss population. Five patients had
a history of malabsorption; however, none had T1D [66].
Investigators reported that the expected risk for EATCL is
12.4/100 000 in patients with T1D over a 60-year period
and suggested that the risk of developing EATCL alone is
not high enough to warrant routine screening for CD in
T1D [66].
11.3. Reproduction. CD has been associated with reproduc-
tive problems at diﬀerent time points in adult populations.
Men with CD have been found to have a greater incidence of
sexual dysfunction, hypogonadism, and poor semen quality
[136]. Delayed menarche, increased secondary amenorrhea,
and early menopause have been documented in women
newly diagnosed with CD [137, 138]. In women following
a GFD for an extended period of time, however, no
diﬀerence was found from controls in terms of the timing
and frequency of these events [139]. Rates of spontaneous
abortions have also been reported to be signiﬁcantly higher
in women with untreated CD than healthy controls [137,
138]. In addition, patients with untreated CD who have
successful pregnancies have been found to have more
low-birth weight babies than healthy controls [140–143].
However a population-based study done in the UK found no
diﬀerence in fertility rates or pregnancy outcomes between
women with untreated CD and healthy controls, making it
diﬃcult to elucidate the true impact of CD on fertility in
women [144]. A single study done in Italy compared the
long-term reproductive outcomes of adults diagnosed with
CD in childhood to those diagnosed with CD later in life.
Researchers did not ﬁnd a diﬀerence in the age at menarche,
the number of pregnancies or the number of abortions
between patients who remained on GFD from childhood,
patients who reverted back to a gluten-containing diet after
a minimum of one year (diagnosed in childhood), and
patients who had never been on a GFD (newly diagnosed).
However, patients diagnosed with CD as adults that had
never followed a GFD and patients who reverted back
to a gluten-containing diet had signiﬁcantly lower weight
babies and an increased incidence of threatened abortions
than patients who had been following a strict GFD since
diagnosis in childhood [145]. To our knowledge no studies
have examined the impact of CD on reproduction in the
T1D population. Although the impact of untreated CD
on fertility is not completely understood at this point,
the literature does suggest a shortened fertility period for
w o m e nw i t hC Da n dag r e a t e rr i s ko fl o w - b i r t hw e i g h t
babies.
11.4. Long-Term Mortality Risk. There is epidemiologic
evidence from Sweden, Germany, and the US which describe
increased mortality rates in adult patients with undiagnosed
celiac disease. A recent study evaluated TTG and EMA
antibodies from blood samples fortuitously obtained from
a historical cohort of US military personnel who had blood
samples saved between 1948 and 1954. The assessment of
subsequent survival showed a fourfold higher mortality risk
(3.9, CI 2.0–7.5, P<. 001) for CD serology positive subjects
than for CD negative subjects [11]. Larger adult German
c o h o r t sw i t he l e v a t e dT T GI g Al e v e l sh a di n c r e a s e da g e -
adjusted hazard ratios or 1.86 (1.01–3.41) for men and 3.92
(1.44–10.71) for women [146]. A Swedish study examined
mortality risk in CD using small intestinal pathology and
reported increased hazard ratio for death in CD of 1.39 (95%
CI 1.33–1.45) in relation to age and sex-matched controls
from the general population (146). Mortality in pediatric
CD (0–19 years) was also increased (HR 1.9; 1.25–2.89). The
majority of this increased mortality risk was malignancy or
cardiovascular disease related. The numbers of patients in
these studies is small and cause of death is variable, but
they suggest that additional, hitherto undetermined risk may
be present, inﬂuencing long-term health and survival in
patients with serology positive, undiagnosed CD.
12. The ScreeningDilemma
Many patients and their caregivers are apprehensive about
CD screening in the context of T1D. For patients and fami-
lies,diabetesisachallengingconditionrequiringdailyeﬀorts
to balance meals, activity, and insulin to maintain adequate
metabolic control. In adult diabetic patients, the presence of
complications is associated with worsened quality of life [41,
42]. The impact of an additional chronic disease, such as CD,
may substantially aﬀect the quality of life in such patients,
although research has not evaluated this question directly.
Clinicians are also challenged by the fact that while screening
tests are safe and eﬀective, follow-up of positive serologic
screensrequiresaccesstogastroenterologicconsultationwith
invasive testing, as biopsy conﬁrmation of intestinal damage
remains the diagnostic gold standard. Lastly, maintaining a
strict GFD in addition to a diabetic diet requires additional
time, eﬀort, and expense. It is not surprising that most T1D
patients struggle with strict adherence to a GFD (Table 3).
Signiﬁcant gaps exist in our understanding of the natural
history of undiagnosed CD in T1D patients. We do not know
if the outcomes of those identiﬁed by screening are similar
to those who are clinically identiﬁed nor is it clear whether
earlier identiﬁcation, before the onset of clinical symptoms,
impacts long-term outcome. Treatment options beyond a
strict GFD, particularly for asymptomatic patients, must
be explored as well. This would also beneﬁt symptomatic
patients who are not entirely compliant with a GFD. We also
needtodetermineifaminimalthresholdofgluteninthediet
exists and is safe. In the long term, the impact of screening
and treatment as they pertain to clinically relevant outcomes
such as bone mineralization, diabetes control, and wellbeing
are important questions worthy of study.International Journal of Pediatric Endocrinology 9
6 months after GFD initiation:
assess compliance
repeat TTG/dietician assessment
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(GFD)
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patients with type 1 diabetes
If IgA level low∗
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Figure 1: Proposed Screening Schema for Patients At-risk for CD. ∗Low IgA levels may require additional testing of total immunoglobulins.
∗∗DXA scans should be considered for patients at baseline especially with positive evidence of familial osteoporosis, fracture history, delayed
puberty, or abnormal calcium/vitamin D studies.
Despite these concerns, the prevalence of CD is higher in
T1D: between 5–7-fold higher than the general population
[34]. Although some guidelines recommend that screening
for CD should only in symptomatic T1D patients, many
institutions, including ours, have embarked on screening
programsaspartofroutinediabeticcare.Aproposedscreen-
ing strategy with consideration of complication screening
is outlined in Figure 1. In our experience it is diﬃcult to
determine which patient is symptomatic, as most busy dia-
betes clinics do not routinely screen for many of the myriad
of CD-related symptoms. But if clinicians overlook minor
GI symptoms or ascribe them to complications of long-
standing diabetes, a practice of routine testing may detect
these symptomatic patients. From a medical perspective,
numerous advantages may exist in screening asymptomatic
patients with diabetes, including the potential of improved
diabetic control and avoidance of long-term manifestations
of CD. Impaired bone mineralization in adolescent patients
with ongoing, unrecognized intestinal inﬂammation is of
particular concern. Recent population-based and cohort10 International Journal of Pediatric Endocrinology
studiesexaminingadultswithundiagnosed,serologypositive
CD had signiﬁcant higher mortality than controls [11, 146,
147], inferring that undiagnosed celiac disease is not a
benign condition and questioning the ethics of asking or
randomizing patients with CD not to pursue treatment.
ThedilemmaofscreeningforCDinT1Discomplex.The
classicCDpresentationofamiserable,malnourishedtoddler
is no longer typical, as patients who present are sometimes
overweight and come from many ethnic groups. CD and
T1D share common genetic origins and an increasing body
of evidence identiﬁes this intestinal insult as a provocative
factor in the pathogenesis of T1D and other autoimmune
conditions. For these reasons, it is important to emphasize to
clinicians caring for pediatric patients that CD appears at a
much higher rate in patients with diabetes and can present
with multiple gastrointestinal and nonintestinal features.
The challenge remains to follow the precept of primum non
nocere:ﬁrstdonoharminourapproachtothesepatientsand
furtherevaluatetherisksandbeneﬁtsofscreeningrelevantto
clinically important outcomes.
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